October 20, 2015 | By Tracy Staton
Hepatitis C drugs were a big-ticket item for Medicare last year. They're on track to be even bigger this year. As ProPublica reports, Medicare Part D spent nearly $4.6 billion on hep C treatments for the first half of 2015--almost as much as paid for 2014 total. And according to script numbers, Gilead Sciences will reap the lion's share of that spending.
Reducing the cost of new hepatitis C drugs
An index of articles pointing the reader to the current controversy over the high price of hepatitis C medications.
No comments:
Post a Comment